摘要
目的:探讨血清早期前列腺癌抗原-2(Early Prostate Cancer Antigen,EPCA-2)、游离型/总PSA(F/TPSA)在前列腺癌(PCa)诊断中的临床应用价值。方法:用酶联免疫吸附测定法(ELISA)分别对前列腺癌组与良性前列腺增生组患者血清进行检测EPCA-2值、F/TPSA值及PSA值,所得数据的分析和处理采用SPSS17.0统计学软件进行。结果:(1)前列腺癌组PSA水平显著高于BPH组,差异有统计学意义(P<0.01)。(2)前列腺癌组FPSA/TPSA水平比值显著低于BPH组,差异有统计学意义(P<0.01)。(3)前列腺癌组EPCA-2水平为(63.45±23.49)ng/mL,而BPH组EPCA-2水平为(16.60±7.62)ng/mL,较前列腺癌组明显为低,差异具有统计学意义(P<0.01)。(4)诊断能力EPCA-2>FPSA/TPSA>PSA。(5)FPSA/TPSA水平与EPCA-2水平之间无相关关系。(6)若将EPCA-2与FPSA/TPSA比值联合应用预测前列腺癌的特异性为90.00%,敏感性为95.00%。结论:EPCA-2、FPSA/TPSA、PSA三者相比在诊断前列腺癌方面的能力排名为EPCA-2>FPSA/TPSA>PSA,并且EPCA-2与FPSA/TPSA比值之间无相关性。若将EPCA-2与FPSA/TPSA比值联合应用在前列腺癌诊断方面可大大提高诊断率,降低活检率。
Objective:To explore the clinical application value of EPCA-2,F/TPSA in the diagnosis of prostate cancer.Methods:Serum EPCA-2value,F/TPSA value,and PSA value of patients with prostate cancer and benign prostatic hyperplasia were detected by enzyme linked immunosorbent assay,respectively.The data were analyzed and processed by SPSS17.0statistical software.Results:(1)The level of PSA in prostate cancer group was significantly higher than that in BPH group,and the difference was statistically significant(P〈0.01).(2)The level of FPSA/TPSA in Prostate cancer group was significantly lower than that in BPH group,and the difference was statistically significant(P〈0.01).(3)EPCA-2level in prostate cancer group was(63.45±23.49)ng/mL;while it was(16.60±7.62)ng/mL in BPH group.The level in prostate cancer group was significantly higher than that in BPH group,and the difference was statistically significant(P〈0.01).(4)Diagnostic capabilities were:EPCA-2〉FPSA/TPSA〉PSA.(5)There was not any correlation between FPSA/TPSA level and EPCA-2 levels.(6)If EPCA-2value and FPSA/TPSA ratio were combined to diagnose prostate cancer,the specificity was of 90.00%,the sensitivity of 95.00%.Conclusions:Sort diagnostic capabilities are:EPCA-2〉FPSA/TPSA〉PSA.No correlation was existed between EPCA-2value and FPSA/TPSA ratio.The application of both EPCA-2level and FPSA/TPSA ratio in the diagnosis of prostate cancer can greatly improve diagnostic rate of prostate cancer,and reduce biopsy rate.
出处
《黑龙江医药科学》
2014年第4期7-8,共2页
Heilongjiang Medicine and Pharmacy
关键词
前列腺癌
良性前列腺增生
早期前列腺癌抗原-2
前列腺特异抗原
prostate cancer(PCa)
benign prostatic hyperplasia(BPH)
early prostate cancer antigen-2(EPCA-2)
prostate specific antigen